Replies to post #145665 on Biotech Values

[p3analyze]

EGFR inhibitors are known to accelerate disease in some patien

Although EGFR TKI's seem to antagonize chemo when it is combined with chemo - they do have single agent activities for tumors with EGFR mutation, and at worst a non-activitiy for those without EGFR mutation. The gist of IPASS study which you cited was that among patients without EGFR mutation, EGFR TKI doesn't do as well a job as platinum-containing doublet.

With that in mind, BATTLE trial provided a hint that single agent Sorafenib works in a Kras mutant subset of the EGFR Mutation negative subset which is known to be resistant to EGFR TKI (http://www.ncbi.nlm.nih.gov/pubmed/20022659).